Our Team
Personalized Precision
with Patient Focus
RadioVaxX GmbH
Our Team
Radio Precision Oncologist and Founder
Prof. Dr. Richard P. Baum
Prof. Dr. Richard Paul Baum is one of the leading scientists in the field of radiomolecular precision oncology. In his more than thirty years as a physician, he has successfully treated tens of thousands of patients. First at the University Hospital in Frankfurt/Main and later as head physician of the Zentralklinik Bad Berka. In the process, he has made a significant contribution to establishing, improving and further developing radiomolecular precision oncology.
Since 2020, he has been working at the Curanosticum Wiesbaden-Frankfurt (at DKD). With RadioVaxX, Professor Baum aims to further advance the implementation of the idea of theranostics as an alternative diagnostic and therapeutic approach. The rapid translation from research to the clinic („from bench to bedside“) and the application of new radiopharmaceuticals should be made possible. In this way, Professor Baum would like to continue long-standing doctor-patient relationships and offer patients new perspectives with ever better therapy options.
Molecular Scientist and Founder
Dr. Ralph M. Wirtz
Dr. Ralph Markus Wirtz is a leading international molecular biologist who is very successfully involved in a variety of research projects and companies, all of which improve and develop innovative technologies to combat oncological disease and make them available for patients.
Since 2010, he has servd as CEO of Stratifyer, acompany that develops molecular testing methods for in vitro diagnostics, is responsible for study design and translational conduction of clinical studies. He has founded and leads a number of interdisciplinary professional cancer organizations for individualized medicine.
Dr. Ralph M. Wirtz has built up a worldwide network that translates deep insights into tumor biology from clinical trials into personalized medicine approaches via molecular registries into Real World application.
CRO Management
Dr. Matthias Braun
Dr. Matthias Braun is a chemist and long-time manager in leading and globally operating pharmaceutical companies (most recently Sanofi).
Mr. Braun worked for 30 years in Sanofi-Aventis Deutschland GmbH and predecessors. The last 17 years thereof he served as General Manager for Active Ingredient Production as well as Manufacturing on the German Board of management. He retired from Sanofi until 1.6.2022.
In his professional career, he covered the areas of drug (API) development, product transfer, production, production management, sterile manufacturing and distribution.
In recent years he has been involved with lean, process and production equipment optimization.
He came in contact with immunology already in the minor of his PhD and afterwards in a number of development and launch projects.
Radiochemistry & Project Management
Dr. Lukas Greifenstein
Dr. Lukas Greifenstein is a chemist with extensive experience in radiopharmaceutical chemistry. In 2020 he established the radiopharmaceutical production at Curanosticum Wiesbaden – Frankfurt, Center for Advanced Radiomolecular Precision Oncology which he has led since then.
Between 2014 and 2020 he worked as a research fellow at the Institute of Nuclear Chemistry of the Johannes Gutenberg-University Mainz, supported by MPGC, DAAD, and ICPO. He specialized in the synthesis, development, and modification of radiopharmaceuticals, their functionalization, with new chelates and targeting structures, and their labeling with a variety of isotopes. This work was carried into clinics around the world in recent years. He recently adapted Ac-225 chemistry at Curanosticum and was involved in the translation of different new clinical therapy approaches including Ac-SSTR antagonist therapy as well as Ac-FAP therapy.
Legal and Business Advisors
Dr. Andreas Walkenhorst
Dr. Andreas Walkenhorst is a founding partner of the law firm TERGAU & WALKENHORST. He completed his studies in physics with a focus on light engineering and solid state physics in 1989 and subsequently received his doctorate from the Technical University of Darmstadt. After a research stay at the renowned University of Maryland (College Park, USA), he was trained as a patent engineer and patent attorney at Siemens AG. From 2000 onwards, Dr. Andreas Walkenhorst worked for the law firm Tergau & Pohl and founded the law firm TERGAU & WALKENHORST together with Dietrich Tergau in 2011. He is to provide patent law support for the project(s). For Dr. Walkenhorst, his investment company Nidac GmbH will participate in the company to be founded.
Martin Bosch
Martin Bosch is one of the managing directors of St. Josefs-Hospital Wiesbaden. The „JoHo“ is an innovative hospital with supraregional appeal in the Rhine-Main metropolitan region and has a major oncological focus. In addition to the original medical and corporate development, an essential part of the corporate strategy is the networking with other service providers and the implementation of innovative business models. Together with its subsidiary JoHo Consulting GmbH, JoHo will provide administrative and commercial support for the project.